Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Braze Fiscal Q4 2026 Earnings Call - AI Product Launches and Enterprise Momentum Re-accelerate Growth
Braze closed fiscal Q4 2026 with clear acceleration: revenue of $205.2 million, up 28% year over year, stronger bookings, and swelling enterprise traction that lifted ARR past $800 million and remaini...
- Q4 revenue $205.2 million, up 28% year over year and 8% sequentially; organic revenue growth for the quarter implied at 24.3% after Decisioning Studio contribution.
- Braze passed $800 million in ARR early in fiscal 2027 and reported over $1 billion in remaining performance obligations, signaling larger, longer customer commitments.
- Trailing 12-month dollar-based net retention inflected to 109%, a third straight quarter of year-over-year acceleration and a positive signal for upsell health.
- +13 more takeaways
AAR Corp Third Quarter FY2026 Earnings Call - Aftermarket Momentum Masks Near-Term Integration Drag
AAR reported a clean beat on growth and cash flow, driven by outsized strength in parts distribution, steady government demand, and accelerating Trax software adoption. Revenue was up 25% year over ye...
- Total sales grew 25% year over year to $845 million, with adjusted EBITDA up 26% to $102.1 million and adjusted diluted EPS up 26% to $1.25 per share.
- Organic adjusted sales growth was 14% for the quarter, led by 36% organic growth in new parts distribution.
- New parts distribution grew 62% in total, with roughly two thirds of that growth coming from same-store expansion and the remaining third from new contract wins.
- +12 more takeaways
TELA Bio Q4 2025 Earnings Call - Commercial overhaul keeps momentum, but company paces 2026 guidance amid execution risks
TELA Bio closed 2025 with 16% full year revenue growth to $80.3 million and a record Q4 at $20.9 million, powered by strong unit growth, European traction, and early adoption of LIQUIFIX. Management c...
- Revenue and profitability snapshot: Q4 2025 revenue $20.9 million, up 18% year over year; full year 2025 revenue $80.3 million, up 16% year over year.
- Unit growth outpaced revenue growth: OviTex unit sales grew 20% in Q4 and 22% for the year, while PRS unit sales grew 12% in Q4 and for the year, indicating mix dilution is pressuring ASPs.
- Product mix shift: higher share of smaller IHR units and rising inguinal and LPR volume reduced ASPs, management expects continued unit-driven volume growth even as revenue mix normalizes.
- +12 more takeaways
MaxCyte Q4 2025 Earnings Call - $4M SPL Headwind Keeps 2026 Modest, DTx Launch and SeQure Integration Offer Recovery Path
MaxCyte closed 2025 with $33.0 million in revenue, an install base of 857 instruments, and a business reshaped by customer program rationalizations. Management says the shortfall is concentrated, not ...
- Total revenue for full year 2025 was $33.0 million, down 15% from $38.6 million in 2024.
- Core revenue for 2025 was $29.6 million, SPL program related revenue was $3.4 million.
- Q4 2025 revenue was $7.3 million, down 16% year over year; Q4 core revenue was $6.8 million, down 22%.
- +14 more takeaways
Fractyl Health Q4 2025 Earnings Call - Ablation Length Emerges as Key Driver, Pivotal Built to Win
Fractyl doubled down on a clear narrative: the clinical signal for Revita is real, but it depends on two controllable things, patient selection and ablation dose. New analyses from the REMAIN-1 midpoi...
- Post hoc analysis of the REMAIN-1 midpoint cohort reveals a clear, monotonic dose response between duodenal ablation length and post-GLP-1 weight maintenance.
- An ablation length threshold of roughly 16 centimeters or more is associated with the strongest clinical effect; company will use >=16 cm as the operating standard going forward.
- In the full REMAIN-1 pivotal cohort, mean and median ablation lengths exceeded 16 centimeters, and all pivotal investigators were trained to consistently achieve more than 14 centimeters of ablation.
- +12 more takeaways
BioStem Technologies Q4 2025 Earnings Call - BioTissue Acquisition Repositions Firm Toward Hospital Revenue to Offset Medicare Headwinds
BioStem used the Q4 call to announce a sharp strategic pivot. Management closed the BioTissue surgical and wound assets on January 21, 2026, and is reallocating sales and commercial resources toward h...
- BioStem reported Q4 2025 revenue of $10.1 million, nearly flat vs the prior period ($10.5M) but down from $22.7 million in Q4 2024.
- Q4 gross profit was $9.8 million, implying a 97% gross margin, up from 88% in the prior period and 84% in Q4 2024, driven by product mix favoring items without licensing fees.
- Operating expenses jumped to $17.3 million in Q4, primarily due to an $8.8 million allowance for potentially uncollectible receivables from distributor Venture Medical, tied to CMS payment delays and denials.
- +15 more takeaways
BioCardia Q4 2025 Earnings Call - CardiAMP echo data points to potential approval focused on high NT-proBNP subgroup
BioCardia leaned hard on new echocardiography findings from its phase III CardiAMP HF trial, arguing the therapy suppresses pathological ventricular remodeling most convincingly in patients with eleva...
- CardiAMP HF echocardiography core-lab data show left ventricular volume reductions trending in the full cohort with p-values of 0.06 (end-diastolic) and 0.09 (end-systolic), just above conventional significance thresholds.
- Pre-specified subgroup with elevated NT-proBNP produced statistically significant echo benefits: reductions >20 mL/m2 and >15 mL/m2 with p-values of 0.02 and 0.01 respectively.
- Three independent clinical trials now have final or complete data showing consistent directionality: reduced fatal and non-fatal MACE and improved quality of life, strongest in the NT-proBNP high subgroup.
- +13 more takeaways
REPAY Q4 2025 Earnings Call - Exited 2025 with normalized growth, guiding to double-digit 2026 and ~40% Adj. EBITDA
REPAY closed 2025 with a clear pivot back to normalized growth and strong profitability. Q4 revenue was $78.6 million with gross profit of $58.3 million, translating to 10% normalized revenue growth a...
- Q4 revenue was $78.6 million, Q4 gross profit was $58.3 million, with normalized revenue growth of 10% and normalized gross profit growth of 9% year over year after excluding 2024 political media contributions.
- Adjusted EBITDA for Q4 was $32.4 million, implying a 41% Adjusted EBITDA margin; management expects roughly 40% Adjusted EBITDA margins for full-year 2026.
- 2026 guidance: revenue $340 million to $346 million, representing 10% to 12% reported growth and about 7% to 9% normalized growth excluding political media contributions.
- +12 more takeaways
Perma-Fix Environmental Services Q4 2025 Earnings Call - Hanford ramp and permit expansion set stage for a Q2 revenue inflection
Perma-Fix used 2025 to bulk up capacity and regulatory footing, centering its 2026 outlook on the Hanford cleanup ramp and expanded processing at Perma-Fix Northwest. Management highlights a renewed p...
- Revenue and profit snapshot: FY2025 revenue was $61.7 million, up 4.3% from 2024; Q4 revenue was $15.7 million, up 6.9% year over year. FY net loss narrowed to $13.8 million from $20.0 million in 2024.
- Treatment segment strength: Treatment revenue grew materially, up 29% year over year per management commentary, driven by higher volumes and improved plant throughput. Treatment backlog was cited as up 51% to about $1.9 million by the CEO, while the CFO reported a waste treatment backlog of $11.9 million at year end, a discrepancy investors should clarify.
- Permitting milestone at Northwest: Perma-Fix Northwest renewed its permit, expanding permitted liquid mixed waste processing to roughly 1.2 million gallons annually and authorizing macroencapsulation up to 175,000 tons, tripling prior liquid capacity and enabling faster permit mods going forward.
- +13 more takeaways
Leatt Corporation Q4 2025 Earnings Call - International Demand Drives 41% Full-Year Revenue Growth and Margin Expansion
Leatt closed 2025 with a clear breakout year, reporting $61.91 million in revenue, up 41% year over year, powered by a 47% jump in international sales and stronger direct-to-consumer traction. Margins...
- Full-year 2025 revenue was $61.91 million, a 41% increase versus 2024.
- Fourth quarter 2025 revenue was $16.0 million, up 43% year over year.
- International revenues for 2025 were $44.64 million, up 47% year over year and the primary growth engine.
- +12 more takeaways